clinical trial · NCT00859430
Levetiracetam 1000 mg Under Non-Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 22
HealthyLevetiracetamKeppra®
brief summary
The objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fed conditions.
started
Jan 1, 2007
primary completion
Jan 1, 2007
completion
Jan 1, 2007
last updated
Aug 20, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fed Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol